ABSK211 / Abbisko - LARVOL DELTA

Preclinical characterization of ABSK211: A highly potent, orally bioavailable and selective pan-KRAS inhibitor with broad and robust activity in KRAS-driven tumors (AACR 2026) - "Additionally, ABSK211 exhibited robust anti-tumor activity in xenograft models with other KRAS mutations, such as KRAS G12D/S and KRAS G13D. ABSK211 is currently undergoing IND-enabling studies; its superior preclinical profile supports its advancement into clinical studies."

Preclinical • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor • KRAS